πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

6,931 results for β€œThe” Clear

  1. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  2. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial

  3. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  4. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial

  5. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  6. Antipyrine-benzocaine otic solution

    United Therapeutics Europe Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  7. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  8. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  9. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Esophageal Squamous Carcinoma

    phase 2 small molecule active

    1 trial

  10. Apatinib

    The First People's Hospital of Lianyungang

    Malignant Ascites

    phase 2 small molecule active

    1 trial

  11. Apatinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Apatinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Apatinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Apatinib

    The First People's Hospital of Lianyungang

    Thyroid

    phase 2 small molecule active

    1 trial

  15. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  16. Apatinib

    The First People's Hospital of Lianyungang

    Intrahepatic Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  17. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Apatinib Combined With SHR-1210 Injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  19. Apatinib mesylate tablets

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  20. Apatinib+ SHR-1210（CamrelizumabοΌ‰

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  21. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution Γ  diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution Γ  diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution Γ  diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution Γ  diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Apheresis and Bridging Therapy

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 other completed

    1 trial

  23. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  24. Ara-C Group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources